DEF 14A: ENDRA Life Sciences Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

ENDRA Life Sciences is asking stockholders to approve a reverse stock split proposal, with ratios ranging from 1-for-4 to 1-for-35, to increase its stock price and maintain its Nasdaq listing.

Summary

• ENDRA Life Sciences is holding a special meeting on October 28, 2024, to seek stockholder approval for amendments to its Certificate of Incorporation to effect a reverse stock split of its common stock.
• The proposed reverse stock split ratios range from 1-for-4 to 1-for-35, with the specific ratio to be determined by the Board of Directors within one year of the meeting.
• The primary goal of the reverse stock split is to increase the per share market price of ENDRA's common stock to meet the minimum bid price requirements for continued listing on The Nasdaq Capital Market.
• The Board of Directors recommends voting FOR the reverse stock split proposal.
• The record date for determining stockholders eligible to vote at the Special Meeting is September 6, 2024.
• The Special Meeting will be held virtually at www.virtualshareholdermeeting.com/NDRA2024SM.

Sentiment

Score: 4

Explanation: The document is primarily procedural, outlining the need for a reverse stock split to avoid delisting. While the company expresses optimism about attracting new investors, the underlying situation reflects financial challenges and uncertainty.

Positives

• The reverse stock split aims to increase the stock price to meet Nasdaq's minimum bid price requirement, potentially avoiding delisting.
• A higher stock price could attract a broader range of investors, including institutional investors, and improve liquidity.
• The Board has the flexibility to choose the most advantageous reverse stock split ratio within the specified range.
• The company has obtained an extension from Nasdaq to regain compliance, providing additional time to implement the reverse stock split.

Negatives

• There is no guarantee that the reverse stock split will increase the stock price or maintain it above $1.00 in the long term.
• The reverse stock split could decrease the liquidity of the stock due to the reduced number of outstanding shares.
• Some stockholders may end up owning odd lots, which can be more difficult to sell or have higher transaction costs.
• The reverse stock split could be viewed negatively by the market and lead to a decrease in the company's overall market capitalization.
• The Company's August Reverse Stock Split did not have the intended effect of bringing the bid price for our Common Stock over $1.00.

Risks

• The reverse stock split may not be effective in increasing the stock price or maintaining Nasdaq listing compliance.
• Market conditions and the company's performance could still negatively impact the stock price, regardless of the reverse stock split.
• Reduced liquidity and potential decrease in market capitalization could negatively affect investors.
• The company's August Reverse Stock Split did not have the intended effect of bringing the bid price for our Common Stock over $1.00.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement by implementing a reverse stock split, but there is no guarantee of success.

Management Comments

• The Board recommends that you vote your shares FOR the Reverse Stock Split Proposal.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices.

Comparison to Industry Standards

• Many companies in the biotechnology and pharmaceutical industries, particularly those in early stages of development, have used reverse stock splits to maintain listing compliance.
• Comparable companies that have recently undergone reverse stock splits include [hypothetical company A] and [hypothetical company B], which faced similar challenges with Nasdaq's minimum bid price requirement.
• The success of a reverse stock split in maintaining listing and improving stock price varies depending on the company's underlying fundamentals and market conditions.

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, potentially seeing a change in the number of shares they own and the stock's market price.
• Employees may be impacted by the company's ability to maintain its Nasdaq listing, which could affect morale and job security.
• The company's customers and suppliers may be indirectly affected by the company's financial stability and access to capital.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Special Meeting on October 28, 2024.
• The Board of Directors will determine the specific reverse stock split ratio, if approved, and announce it publicly.
• The company will file the Reverse Stock Split Charter Amendment with the Secretary of State of the State of Delaware, if the Board decides to implement the reverse stock split.
• The company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading sessions on or before November 20, 2024.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stockholder meeting, compliance, ENDRA Life Sciences, stock price, listing